Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Trial details
- Registry ID
- NCT01995058
- Phase
- Phase 2
The FDA approved abiraterone (Zytiga(R)) on 28 Apr 2011.
Drug identity checked against registry records
Also recorded as Zytiga(R); abiraterone acetate
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058 | Exelixis | Phase 2 | Terminated | 2014-11Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2011-04-28Day | abiraterone | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA202379", "applicant_as_listed_by_fda": "JANSSEN BIOTECH", "brand_names": ["ZYTIGA"], "active_ingredients": ["ABIRATERONE ACETATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20110428", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |